Search Results - "Osumi, Hiroki"

Refine Results
  1. 1

    Clinical utility of circulating tumor DNA for colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Yamaguchi, Kensei, Zembutsu, Hitoshi

    Published in Cancer science (01-04-2019)
    “…Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its prognosis has improved because of development of diagnosis and…”
    Get full text
    Journal Article
  2. 2

    Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma by Ooki, Akira, Osumi, Hiroki, Fukuda, Koshiro, Yamaguchi, Kensei

    Published in Cancer and metastasis reviews (01-09-2023)
    “…Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into…”
    Get full text
    Journal Article
  3. 3

    Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair by Ooki, Akira, Osumi, Hiroki, Yoshino, Koichiro, Yamaguchi, Kensei

    “…Gastric cancer (GC) is a common malignancy that presents challenges in patient care worldwide. The mismatch repair (MMR) system is a highly conserved DNA…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Clinical impact of Epstein‐Barr virus status on the incidence of lymph node metastasis in early gastric cancer by Osumi, Hiroki, Kawachi, Hiroshi, Yoshio, Toshiyuki, Fujisaki, Junko

    Published in Digestive endoscopy (01-03-2020)
    “…Epstein‐Barr virus‐positive gastric cancer (EBVGC) comprises approximately 9% of all gastric cancers and is associated with a low prevalence of lymph node…”
    Get full text
    Journal Article
  6. 6

    Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma by Ooki, Akira, Osumi, Hiroki, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei

    Published in Therapeutic Advances in Medical Oncology (01-01-2023)
    “…Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a…”
    Get full text
    Book Review Journal Article
  7. 7

    Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival by Ota, Yumiko, Takahari, Daisuke, Suzuki, Takeshi, Osumi, Hiroki, Nakayama, Izuma, Oki, Akira, Wakatsuki, Takeru, Ichimura, Takashi, Ogura, Mariko, Shinozaki, Eiji, Suenaga, Mitsukuni, Chin, Keisho, Yamaguchi, Kensei

    Published in Cancer chemotherapy and pharmacology (01-02-2020)
    “…Purpose In the ATTRACTION-2 trial, nivolumab significantly improved the survival of advanced gastric cancer patients. The pretreatment neutrophil-to-lymphocyte…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication by Osumi, Hiroki, Fujisaki, Junko, Suganuma, Takanori, Horiuchi, Yusuke, Omae, Masami, Yoshio, Toshiyuki, Ishiyama, Akiyoshi, Tsuchida, Tomohiro, Miki, Kazumasa

    Published in PloS one (30-08-2017)
    “…Helicobacter pylori (H. pylori) eradication is usually assessed using the 13C-urea breath test (UBT), anti-H. pylori antibody and the H. pylori stool antigen…”
    Get full text
    Journal Article
  15. 15

    Non‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Takahari, Daisuke, Ooki, Akira, Suzuki, Takeshi, Ota, Yumiko, Nakayama, Izuma, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

    Published in International journal of cancer (01-11-2019)
    “…The Raf murine sarcoma viral oncogene homolog B (BRAFV600E) mutation (MT) in metastatic colorectal cancer (CRC) is a well‐known prognostic indicator and a…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19

    Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer by Osumi, Hiroki, Shinozaki, Eiji, Mashima, Tetsuo, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Ota, Yumiko, Nakayama, Izuma, Takahari, Daisuke, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei

    Published in Cancer science (01-08-2018)
    “…Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third‐line treatment for pretreated…”
    Get full text
    Journal Article
  20. 20

    Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer by Takahashi, Ryo, Nunobe, Souya, Osumi, Hiroki, Takahari, Daisuke, Yamamoto, Noriko, Ida, Satoshi, Kumagai, Koshi, Ohashi, Manabu, Sano, Takeshi, Hiki, Naoki

    Published in Surgery today (Tokyo, Japan) (01-10-2020)
    “…Purpose Patients who receive trastuzumab (T-mab) plus chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer sometimes respond…”
    Get full text
    Journal Article